Treatment choices: still tough to make for challenging myeloma cases?

Inger Nijhof, MD, PhD 

 St. Antonius Hospital, Hematologist,Department of Internal Medicine, The Netherlands

Despite all available treatment options, certain patient subgroups can be very challenging to treat. This e-learning zooms in on these difficult to treat cases.

Approximate time: 1 hour

 

Training Inhoud

Module 2: Treatment choices: still tough to make for challenging myeloma cases?

Accredited for 1 CME point

Start module 2

Inger Nijhof, MD, PhD 

Hematologist,

St. Antonius Hospital,

Department of Internal Medicine,

The Netherlands

Fredrik Schjesvold, MD, PhD 

Hematologist,

Oslo Myeloma Center,

Department of Hematology,

Norway

Isabelle Vande Broek, MD, PhD 

Hematologist,

Vitaz, Sint-Niklaas,

Department of Oncology & Hematology,

Belgium

Agoston Gyula Szabo , MD 

Hematologist,

Righospitalet Copenhagen,

Department of Hematology,

Denmark

Ville Varmavuo, MD, PhD 

Chief Medical Officer in Education,

Kotka,

Internal Medicine,

Finland

Prof. Xavier Leleu, MD, PhD 

Hematologist,

Academic Hospital of Poitiers,

France

Valdas Peceliunas, MD 

Hematologist,

Vilnius University Hospital Santaros Klinikos,

Department of Hematology,

Lithuania

Share this e-learning with your colleagues

Accreditation

Accreditation for this e-learning has been granted for 3 points by:

European Accreditation Council for Continuing Medical Education (EACCME)

Obtain CME points

To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.

Clinical cases

Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.

See all clinical cases